It has been demonstrated that pancreatic NET metastases express lower levels of somatostatin, and the knockdown of somatostatin in pancreatic NET cell lines increases metabolic activity, viability, and growth [97]. This evidence concerns the gene SST and pancreatic neuroendocrine tumor.